NasdaqCM - Nasdaq Real Time Price USD

Clene Inc. (CLNN)

Compare

4.8000

-0.1500

(-3.03%)

At close: January 14 at 4:00:01 PM EST

4.7001

-0.10

(-2.08%)

After hours: 7:54:02 PM EST

IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES - January 13, 2025 (NEWMEDIAWIRE) - Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Cl...

NewMediaWire yesterday

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES - (NewMediaWire) - December 30, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiary,...

NewMediaWire 15 days ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - December 19, 2024 - Clene (NASDAQ: CLNN) has announced a $10 million debt ...

NewMediaWire 26 days ago

CLNN
-3.03%
CLNNW
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerated regulatory pathwayCarries a 12% interest rate per annum and is secured by all assets of CleneIncludes conversion feature on 65% of the new debt facility at a fixed conversion price of $5.67, a 130% premium to Clene’s closing stock price on the day of signin

GlobeNewswire 26 days ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - December 11, 2024 - Clene (NASDAQ: CLNN) received FDA guidance on leveragi...

NewMediaWire last month

CLNN
-3.03%
CLNNW
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findingsFDA recommends a follow-up meeting to discuss in more detail the analyses needed to support the accelerated approval pathway Additional NfL biomarker collection and analyses are underway and planned to be completed during the second quarter of 2025Clene is proceeding with its New Drug Application (NDA)

GlobeNewswire last month

CLNN
-3.03%
CLNNW
Clene price target lowered to $83 from $86 at Canaccord

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Clene (CLNN) to $83 from $86 and keeps a Buy rating on the shares. The firm noted they reported results with the key update for that the company held its planned meeting with the FDA on Novemebr 01 to discuss the potential to file a new drug application (NDA) for CNM-Au8 (nanocrystalline gold) for amyotrophic lateral sclerosis (ALS) under an accelerated approval pathway. Canaccord noted the company did not provide any character

TipRanks last month

CLNN
-3.03%
CLNNW
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutesCash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarter of 2025Completed registered direct offering and concurrent private placements to raise $7

GlobeNewswire 2 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES, CA - (NewMediaWire) - October 25, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiar...

NewMediaWire 2 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 21, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidia...

NewMediaWire 2 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 11, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidia...

NewMediaWire 3 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 9, 2024 - Clene (NASDAQ: CLNN) (along with its subsidiaries, ...

NewMediaWire 3 months ago

CLNN
-3.03%
CLNNW
Clene to Present at Upcoming October Conferences

SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October. 2024 Maxim H

GlobeNewswire 3 months ago

CLNN
-3.03%
CLNNW
Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares

Investors who take an interest in Clene Inc. ( NASDAQ:CLNN ) should definitely note that the Independent Chairman of...

Simply Wall St. 3 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES, CA - (NewMediaWire) - October 3, 2024 - Clene (NASDAQ: CLNN), a late clinical-stage biopharm...

NewMediaWire 3 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - (NewMediaWire) - October 2, 2024 - Clene (NASDAQ: CLNN), a late clinical-stage biophar...

NewMediaWire 3 months ago

CLNN
-3.03%
CLNNW
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

Investment led by healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders$7.3 million registered direct offering and concurrent private placements priced at market under Nasdaq rulesAmended debt facility with Avenue Venture Opportunities Fund, L.P. in

GlobeNewswire 3 months ago

CLNN
-3.03%
CLNNW
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities purchase agreement with a heal

GlobeNewswire 3 months ago

CLNN
-3.03%
CLNNW
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES, CA - (NewMediaWire) - September 26, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidi...

NewMediaWire 3 months ago

CLNN
-3.03%
CLNNW
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA)

GlobeNewswire 3 months ago

CLNN
-3.03%
CLNNW

Performance Overview

Return	CLNN	S&P 500
YTD	-4.00%	-1.08%
1-Year	-50.00%	+22.14%
3-Year	-92.03%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Clene Inc. (CLNN)

IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene price target lowered to $83 from $86 at Canaccord

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership

IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences

IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements

IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences

Clene to Present at Upcoming October Conferences

Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares

IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M

IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Performance Overview